Continuous venovenous haemofiltration using a citrate buffered substitution fluid

Anaesthesia and Intensive Care

Volumn 35, Issue 4, 2007, Pages 529-535

  Schmitz, M ^a   Taskaya, G ^a   Plum, J ^a,b   Hennersdorf, M ^a   Sucker, C ^a   Grabensee, B ^a   Hetzel, G R ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b KLINIKUM KASSEL   (Germany)

Author keywords

Acid base balance; Acute renal failure; Continuous renal replacement therapy; Continuous venovenous haemofiltration; Regional citrate anticoagulation

Indexed keywords

ANTICOAGULANT AGENT; BUFFER; CALCIUM; CALCIUM CHLORIDE; CHLORIDE; CITRIC ACID; GLUCONATE CALCIUM; GLUCOSE; MAGNESIUM; POTASSIUM; SODIUM;

ACID BASE BALANCE; ACUTE KIDNEY FAILURE; ADULT; AGED; ANTICOAGULATION; ARTICLE; ARTIFICIAL VENTILATION; BLEEDING DISORDER; BLOOD CLOTTING TIME; BLOOD FLOW; CLINICAL ARTICLE; CONTINUOUS HEMOFILTRATION; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DILUTION; DRUG SUBSTITUTION; ELECTROLYTE BALANCE; EXTRACORPOREAL CIRCULATION; FEMALE; HUMAN; MALE; PATIENT SAFETY;

EID: 34548233723     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0703500411     Document Type: Article

References (34)

1. Hory B, Cachoux A, Toulemonde F. Continuous arteriovenous hemofiltration with low-molecular-weight heparin. Nephron 1985; 41:125.
2. Christin F, Theissen-Laval O, Loeb JP. Danaparoid (orgaran) for continuous venovenous hemodiafiltration in a patient with heparin-induced thrombocytopenia. Ann Fr Anesth Reanim 1998; 17:82-83.
3. Fischer KG, van de Loo A, Bohler J. Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int Suppl 1999; 72:S46-50.
4. Maher FT, Weed LA. Removal of bacteria from fluid path of Skeggs-Leonards-Heisler artificial kidney by continuous millipore filtration. Mayo Clin Proc 1963; 38:441-452.
5. Swartz RD. Hemorrhage during high-risk hemodialysis using controlled heparinization. Nephron 1981; 28:65-69.
6. Turney JH, Dodd NJ, Williams LC, Weston MJ. Prostacyclin prevents endothelial and platelet damage during dialysis. Proc Eur Dial Transplant Assoc 1981; 18:111-116.
7. Zusman RM, Rubin RH, Cato AE, Cocchetto DM, Crow JW, Tolkoff-Rubin N. Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent. N Engl J Med 1981; 304:934-939.
8. Davenport A, Will EJ, Davison AM. Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporeal circuits in patients with combined acute renal and hepatic failure. Nephron 1994; 66:431-437.
9. Martin PY, Chevrolet JC, Suter P, Favre H. Anticoagulation in patients treated by continuous venovenous hemofiltration: a retrospective study. Am J Kidney Dis 1994; 24:806-812.
10. van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, Chang PC. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 1996; 7:145-150.
11. Ward DM, Mehta RL. Extracorporeal management of acute renal failure patients at high risk of bleeding. Kidney Int Suppl 1993; 41:S237-244.
12. Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000; 356:26-30.
13. Ashton DN, Mehta RL, Ward DM, McDonald BR, Aguilar MM. Recent advances in continuous renal replacement therapy: citrate anticoagulated continuous arteriovenous hemodialysis. Anna J 1991; 18:263-267, 329.
14. Flanigan MJ, Pillsbury L, Sadewasser G, Lim VS. Regional hemodialysis anticoagulation: hypertonic tri-sodium citrate or anticoagulant citrate dextrose-A. Am J Kidney Dis 1996; 27:519-524.
15. Gabutti L, Marone C, Colucci G, Duchini F, Schonholzer C. Citrate anticoagulation in continuous venovenous hemodiafiltration: a metabolic challenge. Intensive Care Med 2002; 28:1419-1425.
16. Kirschbaum B, Galishoff M, Reines HD. Lactic acidosis treated with continuous hemodiafiltration and regional citrate anticoagulation. Crit Care Med 1992; 20:349-353.
17. Kutsogiannis DJ, Mayers I, Chin WD, Gibney RT. Regional citrate anticoagulation in continuous venovenous hemodiafiltration. Am J Kidney Dis 2000; 35:802-811.
18. Mehta RL, McDonald BR, Aguilar MM, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 1990; 38:976-981.
19. Mitchell A, Daul AE, Beiderlinden M, Schafers RF, Heemann U, Kribben A et al. A new system for regional citrate anticoagulation in continuous venovenous hemodialysis (CVVHD). Clin Nephrol 2003; 59:106-114.
20. von Brecht JH, Flanigan MJ, Freeman RM, Lim VS. Regional anticoagulation: hemodialysis with hypertonic trisodium citrate. Am J Kidney Dis 1986; 8:196-201.
21. Palsson R, Niles JL. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int 1999; 55:1991-1997.
22. Calatzis A, Toepfer M, Schramm W, Spannagl M, Schiffl H, Citrate anticoagulation for extracorporeal circuits: effects on whole blood coagulation activation and clot formation. Nephron 2001; 89:233-236.
23. Hofmann RM, Maloney C, Ward DM, Becker BN. A novel method for regional citrate anticoagulation in continuous venovenous hemofiltration (CVVH). Ren Fail 2002; 24:325-335.
24. Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2004; 30:260-265.
25. Cointault O, Kamar N, Bories P, Lavayssiere L, Angles O, Rostaing L et al. Regional citrate anticoagulation in continuous venovenous haemodiafiltration using commercial solutions. Nephrol Dial Transplant 2004; 19:171-178.
26. Gupta M, Wadhwa NK, Bukovsky R. Regional citrate anticoagulation for continuous venovenous hemodiafiltration using calcium-containing dialysate. Am J Kidney Dis 2004; 43:67-73.
27. Tolwani AJ, Campbell RC, Schenk MB, Allon M, Warnock DG. Simplified citrate anticoagulation for continuous renal replacement therapy. Kidney Int 2001; 60:370-374.
28. Swartz R, Pasko D, O'Toole J, Starmann B. Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation. Clin Nephrol 2004; 61:134-143.
29. Gabutti L, Ferrari N, Mombelli G, Keller F, Marone C. The favorable effect of regional citrate anticoagulation on interleukin-1beta release is dissociated from both coagulation and complement activation. J Nephrol 2004; 17:819-825.
30. Bohler J, Schollmeyer P, Dressel B, Dobos G, Horl WH. Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: dissociation of complement activation and neutropenia from neutrophil degranulation. J Am Soc Nephrol 1996; 7:234-241.
31. Wiegmann TB, MacDougall ML, Diederich DA. Dialysis leukopenia, hypoxemia, and anaphylatoxin formation: effect of membrane, bath, and citrate anticoagulation. Am J Kidney Dis 1988; 11:418-424.
32. Dhondt A, Vanholder R, Tielemans C, Glorieux G, Waterloos MA, De Smet R et al. Effect of regional citrate anticoagulation on leukopenia, complement activation, and expression of leukocyte surface molecules during hemodialysis with unmodified cellulose membranes. Nephron 2000; 85:334-342.
33. Hofbauer R, Moser D, Frass M, Oberbauer R, Kaye AD, Wagner O et al. Effect of anticoagulation on blood membrane interactions during hemodialysis. Kidney Int 1999; 56:1578-1583.
34. van der Voort PH, Gerritsen RT, Kuiper MA, Egbers PH, Kingma WP, Boerma EC. Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purif 2005; 23:175-180.